Intro & Pathophysiology - Fiery Muscle Mayhem
- Rare, life-threatening pharmacogenetic disorder of skeletal muscle hypermetabolism.
- Triggered by: All volatile halogenated anesthetics (e.g., halothane, sevoflurane, isoflurane), succinylcholine.
- Pathophysiology: "Fiery Muscle Mayhem" due to uncontrolled sarcoplasmic $Ca^{2+}$ release.
- Primary defect: Abnormal ryanodine receptor (RYR1) on sarcoplasmic reticulum (SR).
- Less common: Dihydropyridine receptor (DHPR, CACNA1S gene) defects.
- Mechanism: Triggers → massive, sustained $Ca^{2+}$ efflux from SR → sustained muscle contraction.
- Consequences:
- Hypermetabolism: ↑$O_2$ consumption, ↑$CO_2$ production (early sign).
- ATP depletion, heat production (hyperthermia).
- Muscle damage: Rhabdomyolysis (↑CK, ↑myoglobin), hyperkalemia.
- Lactic acidosis.
⭐ RYR1 gene mutations (chromosome 19q13.1) account for >70% of MH susceptibility; inheritance is typically autosomal dominant.
Triggers & Clinical Features - Alarming Signs Ignite
- Primary Triggers:
- Volatile halogenated anesthetics (e.g., halothane, isoflurane, sevoflurane, desflurane)
- Succinylcholine (depolarizing muscle relaxant)
- Predisposition:
- Genetic susceptibility (e.g., RYR1, CACNA1S gene mutations)
- Rare:
- Extreme physiological stress, heatstroke in susceptible individuals
| Early Signs | Late Signs |
|---|---|
| ↑ ETCO₂ (>55 mmHg) - earliest, most specific | Hyperthermia (rapid ↑ 1-2°C/5min, often >40°C) |
| Tachycardia, Ventricular arrhythmias | Rhabdomyolysis (myoglobinuria, dark urine) |
| Tachypnea (if breathing spontaneously) | Hyperkalemia (peaked T-waves, arrhythmias) |
| Masseter Muscle Rigidity (MMR), Trismus 📌 | Severe metabolic & respiratory acidosis |
| Unstable BP, Mottled skin, Profuse sweating | Disseminated Intravascular Coagulation (DIC) |
| Acute renal failure, Multi-organ dysfunction | |
| %%{init: {'flowchart': {'htmlLabels': true}}}%% | |
| flowchart TD |
Start["⚠️ Malignant Triggers
• Succinylcholine• Volatile gases"]
Calcium["📋 Calcium Release
• ⬆️ Sarcoplasmic Ca2+• RYR1 gene defect"]
Contraction["🩺 Muscle Contraction
• Sustained state• Uncontrolled ATP"]
Hypermetabolism["📋 Hypermetabolism
• ⬆️ O2 consumption• Massive energy use"]
Rigidity["🩺 Muscle Rigidity
• Masseter spasm• Jaw stiffness"]
Rhabdo["🩺 Rhabdomyolysis
• Muscle breakdown• Cell death"]
CO2Prod["🔬 CO2 Production
• ETCO2 > 55 mmHg• Early sign MH"]
HeatProd["📋 Heat Production
• ⬆️ Metabolic heat• Rapid thermogenesis"]
Vitals["⚠️ Vital Signs
• Tachycardia• Tachypnea"]
Hyperthermia["⚠️ Hyperthermia
• Temp > 40 deg C• Late presentation"]
Labs["🔬 Lab Findings
• Hyperkalemia• Myoglobinuria"]
Failure["⚠️ Organ Failure
• Severe acidosis• Multiple failure"]
Start --> Calcium Calcium --> Contraction Contraction --> Hypermetabolism Contraction --> Rigidity Contraction --> Rhabdo
Hypermetabolism --> CO2Prod Hypermetabolism --> HeatProd Hypermetabolism --> Failure
CO2Prod --> Vitals HeatProd --> Hyperthermia HeatProd --> Failure Rigidity --> Failure Rhabdo --> Labs Rhabdo --> Failure Labs --> Failure
style Start fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C style Calcium fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Contraction fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8 style Hypermetabolism fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Rigidity fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8 style Rhabdo fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8 style CO2Prod fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style HeatProd fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E style Vitals fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C style Hyperthermia fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C style Labs fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C style Failure fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C
> ⭐ An unexplained and persistent rise in End-Tidal CO₂ (**ETCO₂ >55 mmHg**) is often the earliest, most sensitive, and most specific sign of an acute Malignant Hyperthermia episode.
## Diagnosis & Differentials - Spotting the Inferno
* **Clinical Suspicion:** Intraoperative ↑ETCO₂, tachycardia, rigidity, hyperthermia.
* **Lab Markers:**
- ↑ ETCO₂ (earliest sign).
- ABG: Mixed acidosis.
- ↑ K⁺, ↑ CK (often > **20,000 IU/L**).
- Myoglobinuria.
* **Confirmatory Tests:**
- Caffeine Halothane Contracture Test (CHCT) - Gold standard (muscle biopsy).
- Genetic testing (RYR1 mutations).
> ⭐ Unexplained, persistent ↑ETCO₂ refractory to increased ventilation is a hallmark early sign of MH.
| Differential | Differentiator |
| :-------------------- | :-------------------------------------------------- |
| Thyroid Storm | Thyroid history, slower onset, goiter |
| Sepsis | Infection signs, hypotension, ↑WBC |
| NMS | Antipsychotics, slow onset, lead-pipe rigidity |
| Pheochromocytoma | Episodic HTN, headache |
| Heat Stroke | Heat exposure, dry skin (classic) |
| Serotonin Syndrome | Serotonergic drugs, myoclonus, GI sx |
## Management & Prevention - Dousing the Flames
**Acute MH Crisis:**
1. **STOP** triggers! Call for help.
2. **Hyperventilate:** **100% O2** (≥**10 L/min**).
3. **Dantrolene:** **2.5 mg/kg** IV. Repeat prn (max **10 mg/kg**).
4. **Cool Patient:** IV cold saline, ice packs. Stop at **38.5°C**.
5. **Treat:**
* Hyperkalemia: Glucose-insulin, $NaHCO_3$.
* Acidosis (pH < **7.2**): $NaHCO_3$ **1-2 mEq/kg**.
* Arrhythmias: Amiodarone/Lidocaine (NO Ca-channel blockers).
6. **Monitor:** ETCO2, core temp, ABG, K+, CK, UO.
7. **ICU Transfer:** Min **24-36h** observation.
```mermaid
%%{init: {'flowchart': {'htmlLabels': true}}}%%
flowchart TD
Start["<b>⚠️ MH Crisis</b><br><span style='display:block; text-align:left; color:#555'>• Suspected Malignant</span><span style='display:block; text-align:left; color:#555'>• Hyperthermia event</span>"]
Init["<b>🛑 Initial Steps</b><br><span style='display:block; text-align:left; color:#555'>• Call for help</span><span style='display:block; text-align:left; color:#555'>• Stop triggers</span>"]
Hypervent["<b>🫁 Ventilation</b><br><span style='display:block; text-align:left; color:#555'>• 100% Oxygen use</span><span style='display:block; text-align:left; color:#555'>• Hyperventilate</span>"]
Dantrolene["<b>💊 Dantrolene</b><br><span style='display:block; text-align:left; color:#555'>• Give 2.5 mg/kg IV</span><span style='display:block; text-align:left; color:#555'>• Muscle relaxant</span>"]
SymptomCheck{"<b>📋 Persist?</b><br><span style='display:block; text-align:left; color:#555'>• Check symptoms</span><span style='display:block; text-align:left; color:#555'>• Monitor status</span>"}
RepeatDantro["<b>💊 Repeat Dose</b><br><span style='display:block; text-align:left; color:#555'>• q5-10min interval</span><span style='display:block; text-align:left; color:#555'>• Max 10 mg/kg</span>"]
Cooling["<b>❄️ Active Cooling</b><br><span style='display:block; text-align:left; color:#555'>• Cold IV fluids</span><span style='display:block; text-align:left; color:#555'>• Surface cooling</span>"]
Arrest["<b>🔬 Lab Monitor</b><br><span style='display:block; text-align:left; color:#555'>• Treat acidosis</span><span style='display:block; text-align:left; color:#555'>• Check K+ levels</span>"]
Supportive["<b>🩺 Support Care</b><br><span style='display:block; text-align:left; color:#555'>• Maintain output</span><span style='display:block; text-align:left; color:#555'>• Monitor dysrhythmia</span>"]
ICU["<b>👁️ Post-Op Care</b><br><span style='display:block; text-align:left; color:#555'>• ICU admission</span><span style='display:block; text-align:left; color:#555'>• 24hr monitoring</span>"]
Start --> Init
Init --> Hypervent
Hypervent --> Dantrolene
Dantrolene --> SymptomCheck
SymptomCheck -->|Yes| RepeatDantro
RepeatDantro --> SymptomCheck
SymptomCheck -->|No| Cooling
Cooling --> Arrest
Arrest --> Supportive
Supportive --> ICU
style Start fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C
style Init fill:#FDF4F3, stroke:#FCE6E4, stroke-width:1.5px, rx:12, ry:12, color:#B91C1C
style Hypervent fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534
style Dantrolene fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534
style SymptomCheck fill:#FEF8EC, stroke:#FBECCA, stroke-width:1.5px, rx:12, ry:12, color:#854D0E
style RepeatDantro fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534
style Cooling fill:#F1FCF5, stroke:#BEF4D8, stroke-width:1.5px, rx:12, ry:12, color:#166534
style Arrest fill:#FFF7ED, stroke:#FFEED5, stroke-width:1.5px, rx:12, ry:12, color:#C2410C
style Supportive fill:#F7F5FD, stroke:#F0EDFA, stroke-width:1.5px, rx:12, ry:12, color:#6B21A8
style ICU fill:#EEFAFF, stroke:#DAF3FF, stroke-width:1.5px, rx:12, ry:12, color:#0369A1
Prevention:
- Identify at-risk: Family Hx, genetic tests (RYR1), muscle biopsy.
- Safe anesthesia: TIVA, regional, N2O.
- Machine prep: Flush O2 (20-100 min), new circuit/absorbent.
- MH cart accessible.
⭐ Dantrolene's mechanism: Blocks Ca²⁺ release from sarcoplasmic reticulum by antagonizing RYR1 receptors.
High‑Yield Points - ⚡ Biggest Takeaways
- MH: A pharmacogenetic disorder (often autosomal dominant, RYR1 gene) of skeletal muscle.
- Triggers: Volatile anesthetics (e.g., halothane, sevoflurane) and succinylcholine.
- Features: Hypermetabolism - early ↑ETCO2, tachycardia, muscle rigidity (masseter spasm); late hyperthermia.
- Pathophysiology: Defective RYR1 receptor causes uncontrolled Ca²⁺ release in muscle cells.
- Treatment: Stop triggers, 100% O2, IV Dantrolene (2.5 mg/kg), active cooling.
- Dantrolene specifically blocks Ca²⁺ release from the sarcoplasmic reticulum.
- Monitor for: Hyperkalemia, rhabdomyolysis, and metabolic acidosis post-episode.